{
    "title": "Novo Nordisk sees faster profit growth on diabetes drug Ozempic",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11380597/Novo-Nordisk-sees-faster-profit-growth-demand-diabetes-drug-Ozempic.html",
    "date": "2022-11-02",
    "keywords": [
        "profit",
        "drug",
        "operating",
        "obesity",
        "wegovy",
        "growth",
        "ozempic",
        "company",
        "production",
        "demand",
        "injection",
        "weightloss",
        "relaunch",
        "burger",
        "driver",
        "jorgensen",
        "approval",
        "market",
        "q3",
        "offlabel",
        "use",
        "currency",
        "analyst",
        "comment",
        "drugmaker",
        "novo",
        "nordisk",
        "outlook",
        "treatment",
        "exchange",
        "target",
        "range",
        "thirdquarter",
        "forecast",
        "refinitiv",
        "end",
        "outage",
        "year",
        "class",
        "glp1",
        "wednesday",
        "weight",
        "indication",
        "benefit",
        "prescription",
        "ceo",
        "high",
        "august",
        "companys",
        "body",
        "june",
        "contractor",
        "filling",
        "december",
        "launch",
        "capacity",
        "marketing",
        "advertising",
        "nature",
        "competition",
        "mounjaro",
        "type",
        "fasttrack",
        "review",
        "surprise",
        "gain",
        "quarter",
        "pill",
        "saxenda",
        "credit",
        "suisse",
        "jacqueline",
        "jason",
        "jane",
        "merriman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}